M
Marco A. Marra
Researcher at University of British Columbia
Publications - 657
Citations - 215376
Marco A. Marra is an academic researcher from University of British Columbia. The author has contributed to research in topics: Gene & Genome. The author has an hindex of 153, co-authored 620 publications receiving 184684 citations. Previous affiliations of Marco A. Marra include BC Cancer Agency & University of Washington.
Papers
More filters
Journal ArticleDOI
Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing
Jeremy Parker,Yaoqing Shen,Erin Pleasance,Yvonne Y. Li,Jacqueline E. Schein,Yongjun Zhao,Richard A. Moore,Joanna Wegrzyn-Woltosz,Kerry J. Savage,Andrew P. Weng,Randy D. Gascoyne,Steven J.M. Jones,Marco A. Marra,Janessa Laskin,Aly Karsan +14 more
TL;DR: In this patient, the molecular variants that the authors believe to be most relevant to the disease presentation most strongly resemble a diffuse large B-cell lymphoma (DLBCL), whereas the gene expression data are most consistent with a low-grade chronic lymphocytic leukemia (CLL).
Journal ArticleDOI
Differential Hive Plots: Seeing Networks Change
TL;DR: The authors introduce the differential hive plot (DHP), a layout method based on the comparison of two hive plots (HP) that contains nodes and edges in the difference or intersection of the two networks based on positional similarity in the input HPs.
Journal ArticleDOI
TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis.
K-John Cheung,Nathalie A. Johnson,Joslynn G. Affleck,Tesa M. Severson,Christian Steidl,Susanna Ben-Neriah,Jacqueline E. Schein,Ryan Morin,Richard D. Moore,Sohrab P. Shah,Hong Qian,Jessica E. Paul,Adele Telenius,Betty Lai,Thomas Relander,Wan L. Lam,Kerry J. Savage,Joseph M. Connors,Carolyn J. Brown,Marco A. Marra,Randy D. Gascoyne,Douglas E. Horsman +21 more
TL;DR: It is proposed that TNFRSF14, a gene previously implicated in growth inhibition and Fas-induced apoptosis, is a candidate tumor suppressor gene in FL.
Journal ArticleDOI
The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL
Daisuke Ennishi,Aixiang Jiang,Merrill Boyle,Brett Collinge,Bruno M. Grande,Susana Ben-Neriah,Graham W. Slack,Pedro Farinha,Diego Villa,Anja Mottok,Barbara Meissner,Saeed Saberi,Ali Bashashati,Kerry J. Savage,Laurie H. Sehn,Robert Kridel,Marco A. Marra,Sohrab P. Shah,Christian Steidl,Joseph M. Connors,Randy D. Gascoyne,Ryan D. Morin,David Scott +22 more
TL;DR: The clinical impact of the DHITsig within a uniformly R-CHOP treated cohort of de novo GCB-DLBCL drawn from a population-based registry, which included the discovery cases showed the same poor prognosis as the non-HGBL-DH/TH-BCL2 cases.
Journal ArticleDOI
Clinical outcomes after whole genome sequencing in patients with metastatic non-small cell lung cancer.
Erica S Tsang,Yaoqing Shen,Negar Chooback,Cheryl Ho,Martin R. Jones,Daniel J. Renouf,Howard John Lim,Sophie Sun,Stephen Yip,Erin Pleasance,Yussanne Ma,Yongjun Zhao,Andrew J. Mungall,Richard A. Moore,Steven J.M. Jones,Marco A. Marra,Janessa Laskin +16 more
TL;DR: The Personalized OncoGenomics program at the BC Cancer Agency integrates whole genome (DNA) and RNA sequencing into practice for metastatic malignancies and examines patients with advanced cancer for the first time.